Apolipoprotein e polymorphism and clinical disease phenotypes in arab patients with schizophrenia

Neuropsychobiology

Volumn 60, Issue 2, 2009, Pages 67-72

  Akanji, A O ^a   Ohaeri, J U ^a   Al Shammri, S N ^a   Fatania, H R ^b  

^a KUWAIT UNIVERSITY   (Kuwait)

^b Psychological Medicine Hospital Kuwait   (Kuwait)

Author keywords

APOE polymorphism; Apolipoproteins; Arabs; Clinical phenotypes; Disease outcome; Schizophrenia

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ARAB; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGE OF ONSET; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ARABS; FAMILY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA; SEX FACTORS; YOUNG ADULT;

EID: 70049106107     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000236446     Document Type: Article

References (35)

1. Carlin C, Murray L, Graham D, Doyle D, Nicoll J: Involvement of apolipoprotein E in multiple sclerosis: Absence of remyelination associated with possession of the APOE- 2 allele. J Neuropath Exp Neurol 2000; 59: 361-367.
2. Mahley RW: Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
3. Siest G, Pillot T, Regis-Bailly A, Leininger- Muller B, Steinmetz J, Galteau MM, Visvikis S: Apolipoprotein E: An important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41: 1068-1086.
4. Schürhoff F, Krebs MO, Szke A, Loze JY, Goldberger C, Quignon V, Tignol J, Rouillon F, Laplanche JL, Leboyer M: Apolipoprotein E in schizophrenia: A French association study and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2003; 119B: 18-23.
5. Fido AA, Razik MA, Mizra I, el-Islam MF: Psychiatric disorders in prisoners referred for assessment: A preliminary study. Can J Psychiatry 1992; 37: 100-103.
6. el-Hilu SM, Mousa R, Abdulmalek H, Kamel N, Zohdi M, al-Aamriti M: Psychiatric morbidity among foreign housemaids in Kuwait. Int J Soc Psychiatry 1990; 36: 291-299.
7. al-Ansari EA, Emara MM, Mirza IA, el-Islam MF: Schizophrenia in ICD-10: A field trial of suggested diagnostic guidelines. Compr Psychiatry 1989; 30: 416-419.
8. Malasi TH, Mirza IA, el-Islam MF: Factors influencing long-term psychiatric hospitalisation of the elderly in Kuwait. Int J Soc Psychiatry 1989; 35: 223-230.
9. Krystal JH, D'Souza DC, Sanacora G, Goddard AW, Charney DS: Current perspectives on the pathophysiology of schizophrenia, depression and anxiety disorders. Med Clin North Am 2001; 85: 559-577.
10. American College of Medical Genetics/ American Society of Human Genetics Working Group on ApoE and Alzheimer's Disease: Statement on use of apolipoprotein E testing for Alzheimer disease. JAMA 1995; 274: 1627-1629.
11. World Health Organization: International Statistical Classification of Diseases and Related Health Problems, 10th Revision. WHO, Geneva, 1992.
12. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
13. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N: SCAN - Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990; 47: 589-593.
14. Kay SR, Fiszbein S, Opler LA: The Positive and Negative Symptom Scale. Schizophr Bull 1987; 13: 331-355.
15. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1981.
16. Handoko HY, Nancarrow DJ, Hayward NK, Ohaeri JU, Aghanwa H, McGrath JJ, Levinson DF, Johns C, Walters MK, Nertney DA, Srinivasan TN, Thara R, Mowry BJ: Tumor necrosis factor haplotype analysis amongst schizophrenia probands from four distinct populations in the Asia-Pacific region. Am J Med Genet 2003; 121B:1-6.
17. Akanji AO, Al-Sulaiman A, Kinatamitath P, Safar F, Al-Zaid K, Mojiminiyi OA: Profile of hyperlipidaemic patients in Kuwait: Frequency of cardiovascular disease risk factors at presentation and initial response to treatment. J Kuwait Med Assoc 1997; 29: 25-33.
18. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 1990; 31: 545-548.
19. Harrington CR, Roth M, Xuereb JH, Mc- Kenna PJ, Wischik CM: Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia. Neurosci Lett 1995; 202: 101-104.
20. Lee MK, Park AJ, Nam BY, Min KJ, Kee BS, Park DB: Apolipoprotein E genotype in Korean schizophrenic patients. J Korean Med Sci 2001; 16: 781-783.
21. Chen JY, Hong CJ, Chiu HJ, Lin CY, Bai YM, Song HL, Lai HC, Tsai SJ: Apolipoprotein E genotype and schizophrenia. Neuropsychobiology 1999; 39: 141-143.
22. Martorell L, Virgos C, Valero J, Coll G, Figuera L, Joven J, Pocovi M, Labad A, Vilella E: Schizophrenic women with the APOE epsilon 4 allele have a worse prognosis than those without it. Mol Psychiatry 2001; 6: 307-310.
23. Kimura T, Shono M, Yokota S, Ishizuka K, Watanabe M, Takamatsu J, Miyakawa T: Apolipoprotein E epsilon4 and tardive dyskinesia in a Japanese population. J Psychiatr Res 2000;34: 329-332.
24. Durany N, Riederer P, Cruz-Sanchez FF: Apolipoprotein E genotype in Spanish schizophrenic patients. Psychiatr Genet 2000; 10: 73-77.
25. Kimura T, Yokota S, Igata-Yi R, Shono M, Takamatsu J, Miyakawa T: Apolipoprotein E epsilon2 allele and early onset schizophrenia. Neurosci Lett 1997; 231: 53-55. (Pubitemid 27366287)
26. Igata-Yi R, Igata T, Ishizuka K, Kimura T, Sakamoto S, Katsuragi S, Takamatsu J, Miyakawa T: Apolipoprotein E genotype and psychosis. Biol Psychiatry 1997; 41: 906-908.
27. Moberg PJ, Arnold SE, Roalf DR, Balderston CC, Abbazia J, Kohler CG, Gur RE, Turetsky BI: Apolipoprotein E genotype and odor identification in schizophrenia. J Neuropsychiatry Clin Neurosci 2006; 18: 231-233.
28. Xu MQ, St Clair D, He L: Meta-analysis of association between ApoE epsilon4 allele and schizophrenia. Schizophr Res 2006; 84: 228-235.
29. Halford J, Mazeika G, Slifer S, Speer M, Saunders AM, Strittmatter WJ, Morgenlander JC: APOE2 allele increased in tardive dyskinesia. Mov Disord 2006; 21: 540-542.
30. Kampman O, Anttila S, Illi A, Mattila KM, Rontu R, Leinonen E, Lehtimki T: Apolipoprotein E polymorphism is associated with age of onset in schizophrenia. J Hum Genet 2004; 49: 355-359.
31. Liu W, Breen G, Zhang J, Li S, Gu N, Feng G, Bai S, Shen T, Yu A, Xue H, St Clair D, He L: Association of APOE gene with schizophrenia in Chinese: A possible risk factor in times of malnutrition. Schizophr Res 2003; 62: 225-230.
32. Hong CJ, Yu YW, Lin CH, Song HL, Lai HC, Yang KH, Tsai SJ: Association study of apolipoprotein E epsilon4 with clinical phenotype and clozapine response in schizophrenia. Neuropsychobiology 2000; 42: 172-174.
33. Kimura T, Shono M, Yokota S, Igata-Yi R, Takamatsu J, Miyakawa T: Apolipoprotein E epsilon3 allele is not a risk factor of schizophrenia: A study of 314 Japanese patients. Neuropsychobiology 2000; 42: 66-68.
34. Thibaut F, Van Der Elst A, Campion D, Martin C, Coron B, Dollfus S, Frebourg TH, Petit M: Apolipoprotein E-varepsilon4 frequency in deficit schizophrenia. Eur Psychiatry 1999; 14: 148-151.
35. Arnold SE, Joo E, Martinoli MG, Roy N, Trojanowski JQ, Gur RE, Cannon T, Price RA: Apolipoprotein E genotype in schizophrenia: Frequency, age of onset, and neuropathologic features. Neuroreport 1997; 8: 1523-1526.